AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"TriLink BioTechnologies","sponsor":"Imperial College London","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TriLink BioTechn & Imperial College London collaborate to produce saRNA for COVID-19 vaccine development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"TriLink BioTechnologies","sponsor":"Chula Vaccine Research Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TriLink BioTechnologies\u00ae Extends Global Support of Covid-19 Vaccine Development into APAC Region with the Chula VRC Bangkok","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"TriLink BioTechnologies","sponsor":"EyeGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TriLink BioTechnologies\u00ae Extends EyeGene Partnership for COVID-19 Vaccine Development in South Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"TriLink BioTechnologies","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TriLink BioTechnologies, Part of Maravai LifeSciences, Announces Cooperative Agreement With Department of Defense","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by TriLink BioTechnologies

    Menu

    TriLink BioTechnologies

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              TriLink BioTechnologies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TriLink BioTechnologies, Part of Maravai LifeSciences, Announces Cooperative Agreement With Department of Defense

              Details:

              The agreement includes funding for TriLink’s planned expansion of its nucleic acid production capabilities in San Diego, California. TriLink has experienced substantial demand for a wide range of nucleic acid products in support of multiple COVID-19 mRNA vaccine.

              Lead Product(s): mRNA Covid-19 Vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: Department of Defense

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement May 24, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TriLink BioTechnologies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TriLink BioTechnologies® Extends EyeGene Partnership for COVID-19 Vaccine Development in South Korea

              Details:

              EyeGene expected to utilize TriLink’s CleanCap® technology and modified UTP manufactured by TriLink in the production of its EG-COVID mRNA COVID-19 vaccine for clinical trials.

              Lead Product(s): EG-COVID mRNA COVID-19 vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: EG-COVID

              Highest Development Status: IND Enabling Product Type: Vaccine

              Partner/Sponsor/Collaborator: EyeGene

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration October 04, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TriLink BioTechnologies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TriLink BioTechnologies® Extends Global Support of Covid-19 Vaccine Development into APAC Region with the Chula VRC Bangkok

              Details:

              The ChulaCov19 mRNA Covid-19 Vaccine Development Program aims to expand access to an mRNA Covid-19 vaccine in Thailand and other low-to-middle-income countries (LMICs) in Asia.

              Lead Product(s): ChulaCov19 mRNA Vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Chula - Cov19

              Highest Development Status: Phase I Product Type: Vaccine

              Partner/Sponsor/Collaborator: Chula Vaccine Research Center

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership August 02, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TriLink BioTechnologies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TriLink BioTechn & Imperial College London collaborate to produce saRNA for COVID-19 vaccine development

              Details:

              Under this development partnership, TriLink will use its robust RNA manufacturing capabilities to respond to the global need for vaccine support against COVID-19.

              Lead Product(s): Self-amplifying RNA vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Imperial College London

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership April 28, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biopharma Group offers CDMO services with expertise in contract R&D for dried products & liquid formulations.
              Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
              Post Enquiry
              POST ENQUIRY